The short answer: Lu-177 PSMA therapy used to require both a failed hormone drug and failed chemotherapy before you could get it. A 2025 FDA expansion - based on the PSMAfore trial - changed that. Men with newly diagnosed metastatic castration-resistant prostate cancer (mCRPC) who have had an androgen receptor pathway inhibitor (ARPI) drug may now qualify before ever starting taxane-based chemotherapy.
This article covers the PSMA track: Lu-177 PSMA radioligand therapy for prostate cancer. If you or someone close to you has just been told that prostate cancer is now castration-resistant and has spread to other parts of your body, this guide explains what the timing shift means for your options right now.
What Is Metastatic Castration-Resistant Prostate Cancer?
Prostate cancer depends on androgens - male hormones - to grow. Hormone therapy, also called androgen deprivation therapy (ADT), lowers androgen levels in the body to slow the cancer. When the cancer starts growing again despite ADT, it is called castration-resistant prostate cancer. When it has also spread - most often to bones, lymph nodes, or other organs - it becomes metastatic castration-resistant prostate cancer, or mCRPC.
A new mCRPC diagnosis is an important decision point in treating prostate cancer. More treatment options are available today than at any previous point, but making sense of the sequence - what comes when, and why - takes careful thought and often a specialist review.
What Is Lu-177 PSMA Therapy?
Lu-177 PSMA therapy is a type of radioligand therapy (RLT). A molecule is designed to bind to a protein called PSMA (prostate-specific membrane antigen). Most prostate cancer cells carry high levels of PSMA. That molecule carries a radioactive atom - lutetium-177 - that delivers radiation directly to PSMA-expressing cancer cells, while protecting the surrounding healthy tissue.
The brand name is Pluvicto (lutetium Lu 177 vipivotide tetraxetan). You receive it as an IV infusion every six weeks, for up to six cycles. For a full explanation of how this therapy works at the cellular level, read our guide on how Lu-177 PSMA targets and treats metastatic prostate cancer.
Why Was Lu-177 PSMA Saved for Late in Treatment?
When the FDA first approved lutetium Lu 177 vipivotide tetraxetan in March 2022, it was for men with PSMA-positive mCRPC who had already received at least one ARPI drug and at least one taxane-based chemotherapy regimen. Patients had to try both and progress through both before they could get this therapy.
The FDA based its approval on the VISION trial, a large randomized study. VISION showed that adding lutetium Lu 177 vipivotide tetraxetan to standard care increased median overall survival from 11.3 months to 15.3 months compared to standard care alone, per the FDA's original approval notice. This was a positive result in advanced cancer.
But the eligibility requirement created a problem. Men who were newly diagnosed with mCRPC and had not yet had a taxane drug did not qualify under the original label. They had to go through chemotherapy first - and only then, if the disease kept progressing, could they consider Lu-177 PSMA. For men who could not tolerate chemotherapy because of age or other health conditions, the therapy was effectively out of reach.
Why Is Lu-177 PSMA Now Available Before Chemotherapy?
In March 2025, the FDA expanded the approved indication based on the results of the PSMAfore trial (NCT04689828). The new label covers adults with PSMA-positive mCRPC who have received ARPI therapy and whose doctor believes it is appropriate to delay taxane-based chemotherapy, according to the FDA's expansion announcement.
PSMAfore enrolled 468 patients with mCRPC who had progressed on one ARPI drug and were believed to be appropriate to delay chemotherapy. Researchers randomly assigned patients to receive lutetium Lu 177 vipivotide tetraxetan or a different ARPI drug. The result: median radiographic progression-free survival (rPFS) was 9.3 months in the Lu-177 group compared to 5.6 months in the ARPI-switch group, with a hazard ratio of 0.41, per ASCO's summary of the approval. A hazard ratio of 0.41 means the risk fell by roughly 59% in the Lu-177 group.
In plain language: for men with mCRPC who have had an ARPI, Lu-177 PSMA therapy now works better than switching to a different ARPI drug. And it no longer requires going through chemotherapy first.
This matters most for patients who are newly diagnosed with mCRPC after ARPI progression - and for those whose doctors prefer to delay chemotherapy because of age, frailty, or other health conditions. For a deeper look at how Lu-177 PSMA and taxane chemotherapy compare in this setting, see our article on Lu-177 PSMA vs taxane chemotherapy after hormone failure.
Has the Shift Gone Even Further?
Yes. In July 2026, the FDA approved lutetium Lu 177 vipivotide tetraxetan in combination with ARPI therapy for adults with PSMA-positive metastatic prostate cancer that is androgen pathway modulation-naive or androgen-sensitive - meaning patients whose cancer has not yet become castration-resistant, per the FDA. This was based on the PSMAddition trial, which studied Lu-177 PSMA therapy combined with an ARPI versus an ARPI alone at an earlier disease stage.
This approval goes beyond the mCRPC stage this article covers. But it reflects a clear direction: evidence increasingly supports earlier use of Lu-177 PSMA therapy. If you have newly diagnosed mCRPC today, the treatment options are very different from what they were three years ago.
Do You Still Need a PSMA-PET Scan to Qualify?
Yes. Across all approved uses, eligibility for lutetium Lu 177 vipivotide tetraxetan requires that your tumors express the PSMA protein at a high enough level. A PSMA-PET scan with an approved radioactive tracer - such as gallium Ga 68 gozetotide - confirms this before starting treatment. The scan shows how strongly your cancer cells take up the tracer. High uptake suggests your cancer is likely to respond to PSMA-targeted therapy. Low or absent uptake means this treatment is unlikely to be effective for your case.
The NCI drug information page for lutetium Lu 177 vipivotide tetraxetan outlines the role of PSMA imaging in patient selection. For a step-by-step guide to what the scan involves and how to prepare, see our article on preparing for your PSMA-PET scan for Lu-177 eligibility.
Who May Not Be a Candidate?
Lu-177 PSMA therapy may not be right for every patient with mCRPC, even after the expanded indication. Factors that may affect eligibility include:
- PSMA-negative disease. If your PSMA-PET scan shows little or no PSMA expression across tumor sites, the targeted molecule cannot reach the cancer cells effectively. You would need to consider alternative treatments.
- Reduced kidney function. Your kidneys clear lutetium-177. Significantly impaired kidney function may raise the risk of kidney damage, and your team will check your renal blood tests carefully before you start treatment.
- Low blood counts. Very low levels of red blood cells, platelets, or white blood cells can indicate that the bone marrow may not tolerate the additional stress of the therapy.
- Very poor general health. Your doctors will assess you individually if you are very frail or have a very low performance status. The six-cycle infusion schedule carries some physical demands.
- High salivary gland uptake on PET. Salivary glands also express PSMA. In some patients, a pattern of high uptake in those glands raises the risk of severe dry mouth during treatment.
These are factors your nuclear medicine and oncology team will review during the eligibility assessment. Not all of them are automatic disqualifiers - your team will weigh the overall risk-benefit picture based on your specific scans and test results.
What Should You Do If You Were Just Diagnosed With mCRPC?
The best thing you can do is make sure your care team is aware of the updated eligibility criteria. Some oncologists - particularly those outside specialist cancer centers or theranostics programs - may not yet be offering the pre-chemotherapy indication as a routine option. The evidence has changed; clinical practice sometimes takes time to follow.
Questions worth raising at your next appointment:
- Has my cancer been assessed for PSMA expression? Can I have a PSMA-PET scan if not?
- Based on the March 2025 FDA expansion, do I qualify for Lu-177 PSMA therapy before chemotherapy?
- If my oncologist prefers chemotherapy first, what is the specific reasoning for that sequence in my case?
- If my PSMA scan shows low expression, what are the alternatives at this stage of mCRPC?
If you want an independent review from a nuclear medicine or theranostics team, you can speak with the Art of Healing Cancer nuclear-medicine team to have your PSMA-PET results and treatment history assessed. They can help determine whether the expanded indication applies to your situation, and what options exist if it does not.
You can send your scans and medical summary for an eligibility review through the Lutetium Therapy contact form. If Lu-177 PSMA does not turn out to be the right fit for your case, the team can help you understand what other treatment options may be appropriate.
When to Talk to Your Doctor
Talk to your oncologist or request a specialist review if: you have just been told your prostate cancer is now castration-resistant and has spread; your PSA is rising despite ARPI therapy; you have not yet had a PSMA-PET scan and want to know whether you qualify for Lu-177 PSMA therapy; or you want to understand whether the pre-chemotherapy 2025 FDA indication applies to your situation. A nuclear medicine or theranostics second opinion can help if your current team is unfamiliar with the updated eligibility criteria.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Did the FDA change the rules about who can get Lu-177 PSMA therapy for mCRPC?
Yes. In March 2025, the FDA expanded the approved use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to include men with PSMA-positive mCRPC who have received an androgen receptor pathway inhibitor (ARPI) drug and whose doctor considers it appropriate to delay taxane-based chemotherapy. This means some men with newly diagnosed mCRPC may now qualify before ever starting chemotherapy.
What did the PSMAfore trial show?
The PSMAfore trial enrolled 468 patients with mCRPC who had progressed on one ARPI drug and were considered appropriate to delay chemotherapy. Patients who received lutetium Lu 177 vipivotide tetraxetan had a median radiographic progression-free survival of 9.3 months, compared to 5.6 months for those who switched to a different ARPI drug. The hazard ratio was 0.41, indicating roughly a 59% reduction in the risk of radiographic cancer progression in the Lu-177 group.
Does this mean I can skip chemotherapy for mCRPC entirely?
Not necessarily. The 2025 expansion applies to patients whose doctor considers it appropriate to delay taxane-based chemotherapy - not necessarily avoid it permanently. Some patients will still need chemotherapy at a later point if the disease continues to progress. Your oncologist and theranostics team can help determine the right sequence for your specific situation.
Do I still need a PSMA-PET scan even with the expanded indication?
Yes. A PSMA-PET scan is required for all approved uses of lutetium Lu 177 vipivotide tetraxetan. The scan confirms that your cancer cells express the PSMA protein at a level high enough for the therapy to be effective. If your tumors show low or no PSMA expression, this treatment is unlikely to work well and is not indicated.
What if my oncologist says I still need chemotherapy before Lu-177 PSMA therapy?
Ask your doctor to explain the reasoning in the context of the 2025 FDA expansion for the PSMAfore indication. If your oncologist is not a specialist in radioligand therapy or nuclear medicine, a second opinion from a theranostics center may help clarify whether you qualify under the updated criteria. Sending your recent PSMA-PET scan and blood results for an independent review is a reasonable first step.
